Consumer Genetic Tests for Wellness
How consumer DNA tests for health, diet, fitness and medicine response are regulated by the FDA by function, where their results mislead, and why raw data needs clinical confirmation.
Content last updated . This page has not been medically reviewed.
What this page covers
Consumer genetic tests analyze a saliva or cheek-swab sample you mail in. MedlinePlus lists the kinds of information they may offer: traits, wellness or lifestyle factors such as sleep and fitness, predicted medicine responses, risk of specific conditions, and ancestry. [1] They are very different tests with very different evidence. This page explains how the FDA treats them by function, and where the claims outrun the science. It does not interpret anyone's DNA results. Labels used: established, mixed, insufficient evidence, no good evidence of benefit, marketing claim and Proper evidence not found (we looked and found nothing usable).What is measured and what is calculated
The lab reads specific DNA variants directly. Everything after that is interpretation: which variants count, what they are linked to, and what advice a company attaches. MedlinePlus says results usually give an estimate of how likely a trait or condition is, not a yes-or-no answer. [2] Different companies do not test the same variants, so they can report different results for the same condition. [3]How the FDA treats consumer tests, by function
The FDA page below is the official source, and it was last updated in 2019, so check the FDA's current lists. In the US:| Function | FDA position described on the page |
|---|---|
| Genetic health risk reports | Companies need FDA clearance before offering their first test; most additional tests may follow without premarket review if they meet set requirements and are not for specific higher-risk uses. [3] |
| Carrier screening | Exempt from premarket review but must follow the regulation's requirements. [3] |
| Cancer predisposition | Considered moderate to high risk and required to come to the FDA for premarket review. [3] |
| Pharmacogenetics (response to medicines) | Premarket review required; the FDA had not authorized any consumer test that predicts response to a specific drug, and issued a safety communication about unapproved claims. [3] |
| General wellness, such as athletic ability | Low risk; the FDA generally does not review these. [3] |
| Ancestry | The FDA does not review these. [3] |
So FDA authorization of one health-risk report does not mean every wellness, diet or fitness report from that or any company has been reviewed. The authorized reports are narrow. For example, one authorized report for BRCA1/BRCA2 covers three specific variants that are most common in people of Ashkenazi Jewish descent and do not represent the majority of variants in the general population. The FDA says that report does not describe overall cancer risk and that the absence of those variants does not rule out others. [3] Laws change and differ by country; this is not legal advice, and we did not verify rules outside the US.
What the evidence shows
Lifestyle, nutrition and fitness reports. MedlinePlus says the link between a single genetic variation and a complex trait like weight, athletic performance or sleep is complicated, and it can be difficult to predict the significance of results. [2] A 2020 analysis of the nutrigenetics services of 45 companies called for guidelines setting minimum quality standards. [4] A 2015 consensus statement from sport and exercise genetics researchers said genetic tests have no role in talent identification or individualized training prescription, and that no child or young athlete should be exposed to such testing for those purposes. [5] Label: no good evidence of benefit for talent prediction; insufficient evidence for gene-based diet or fitness advice in general. For diet trials see DNA-based diets.False positives in raw data. A laboratory reviewed 49 samples sent for confirmation of variants first found in consumer raw data and found that 40% of those variants were false positives; some labeled "increased risk" were classified benign by clinical labs and are common in the population. [6] UK genetics clinicians describe patients who used third-party interpretation sites and presented with "pathogenic" variants that were not actually present. [7] A 2023 systematic review of 43 papers found consumer tests sometimes report false positive or incorrectly interpreted rare variants, and that clinicians had reservations about the validity and utility of the information. [8] Label: mixed; some clinically relevant findings are real, but raw data and third-party reports should not be acted on without confirmation by a clinical lab.
Medicine-response (pharmacogenetic) reports. Many other factors, including age, weight, diet and other medicines, also affect how the body responds to drugs. [2] Do not change a prescription because of a consumer report. The FDA's separate table of gene-drug associations says that listing an association does not necessarily mean the FDA advocates using a pharmacogenetic test before prescribing the medicine. [9]
Privacy, family and insurance
Your results also reveal things about relatives. MedlinePlus notes that privacy may be compromised if a company shares data, is breached, changes ownership or goes bankrupt, and that companies may be required to disclose genetic information to law enforcement. [10] The FDA notes that the US Genetic Information Nondiscrimination Act (GINA) bars health insurers from using genetic information in coverage decisions and limits employers with 15 or more employees, but does not cover certain other insurance such as life, disability and long-term care. [3] See genetic and location data privacy.Who should be careful
- Anyone considering testing for a serious inherited condition: the NHS says you need a doctor's referral for genetic testing on the NHS, and counselling can help you think through risks, benefits and family effects. [11] The FDA suggests discussing results with a genetic counselor or qualified provider. [3]
- Anyone about to change medicines, diet or supplements because of a report: discuss it with a prescriber first.
- Parents considering tests for children's talents: see the consensus statement above.
- People planning life, disability or long-term care insurance, given the GINA gaps.
A negative result is not all-clear. The FDA says that you should continue regular preventive care even after a negative result, and a positive result should not be used to make decisions about treating a disease. [3]
Related reading
Consumer genetic interpretation claims, genetic testing and polygenic risk scores in Longevity, uploading genetic results to apps and AI and the home-testing overview.Frequently asked questions
Are consumer genetic tests approved by the FDA?
It depends on the function. Some health-risk reports have been authorized, while general wellness and ancestry tests are generally not reviewed. [3]
Can a DNA test tell me the best diet or workout for me?
Not reliably. MedlinePlus says linking single variants to complex traits like weight or athletic performance is complicated. [2]
Can a DNA test predict my child's sports talent?
Sport genetics researchers say no, and advise that no child or young athlete be tested for this purpose. [5]
Are raw data results reliable?
Not on their own. In one laboratory review, 40% of variants from consumer raw data were false positives on confirmation. [6]
Should I change my medicines based on a consumer report?
No. The FDA says it has not authorized any consumer test predicting response to a specific drug, so talk with your prescriber. [3]
References
- MedlinePlus Genetics. What is direct-to-consumer genetic testing? Read 2026-10-22.
- MedlinePlus Genetics. What do the results of direct-to-consumer genetic testing mean? Read 2026-10-22.
- U.S. Food and Drug Administration. Direct-to-Consumer Tests. Content current as of 12/20/2019. Read 2026-10-22.
- Direct-to-Consumer Nutrigenetics Testing: An Overview. Nutrients 2020. Read 2026-10-22.
- Direct-to-consumer genetic testing for predicting sports performance and talent identification: Consensus statement. Br J Sports Med 2015. Read 2026-10-22.
- False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care. Genet Med 2018. Read 2026-10-22.
- Direct-to-consumer genetic testing with third party interpretation: beware of spurious results. Emerg Top Life Sci 2019. Read 2026-10-22.
- Direct-to-consumer genetic tests providing health risk information: a systematic review of consequences for consumers and health services. Clin Genet 2023. Read 2026-10-22.
- U.S. Food and Drug Administration. Table of Pharmacogenetic Associations. Content current as of 09/10/2026. Read 2026-10-22.
- MedlinePlus Genetics. What are the pros and cons of direct-to-consumer genetic testing? Read 2026-10-22.
- NHS. Genetic and genomic testing. Page last reviewed 1 March 2023. Read 2026-10-22.